Search
Zilebesiran
go.drugbank.com/drugs/DB18929Investigationalclinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Synonyms: (2S,4R)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2- acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-6,10,17, - triazanonacosan-29-oyl}-4-hydroxypyrrolidin-Armodafinil
go.drugbank.com/drugs/DB06413ApprovedInvestigationalArmodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. … (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Synonyms: (–)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide, R-modafinilCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersOlaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigational[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820] … [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell
Synonyms: 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-oneCategories: MATE 2-K Inhibitors, MATE 1 InhibitorsOmega-3 fatty acids
go.drugbank.com/drugs/DB11133ApprovedInvestigationalNutraceuticalOmega-3 fatty acids are polyunsaturated fatty acids (PUFAs) with a double bond at the third carbon atom from the end of the carbon chain. … Omega-3 fatty acids play a critical role in metabolism and cellular function and they are available as daily supplements. On September 8, 2004, the U.S.
Synonyms: n-3 PUFAs, n-3 fatty acidsMixtures: LIPOMEGA® 10, LIPOMEGA® 20Nadolol
go.drugbank.com/drugs/DB01203ApprovedInvestigational[A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922] … Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.
Mixtures: CORGARETIC (NADOLOL/ BENDROFLUMETIAZIDA) 80/5 MG, Corzide Tab W Nadolol 80mgCategories: MATE 1 Substrates, MATE 2 SubstratesTropicamide
go.drugbank.com/drugs/DB00809Approved[A229958] It is also used in combination with [hydroxyamphetamine] for the same indication. … Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors.
Mixtures: MYDRIASERT 0,28 MG/5,4 MG GÖZ INSERTI ,20 INSERT, MYDRIASERT 0,28 MG/5,4 MG GÖZ INSERTI ,10 INSERTCategories: Heterocyclic Compounds, 1-RingBrolucizumab
go.drugbank.com/drugs/DB14864ApprovedInvestigationalBrolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
Products: Xivubel 120 mg/ml Enjeksiyonluk Çözelti, 1 adet, Pagenax 120mg/ml Solution For InjectionPralidoxime
go.drugbank.com/drugs/DB00733ApprovedInvestigationalVet approvedIf given within 24 hours,after organophosphate exposure, pralidoxime reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase
Categories: Compounds used in a research, industrial, or household settingSynonyms: 2-PAMFlutamide
go.drugbank.com/drugs/DB00499ApprovedInvestigationalAn antiandrogen with about the same potency as cyproterone in rodent and canine species.
Synonyms: α,α,α-trifluoro-2-methyl-4'-nitro-m-propionotoluidide, 4'-nitro-3'-trifluoromethylisobutyranilideCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRavulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigationalRavulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. … [A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis.
Categories: Complement C5 inhibitorsProducts: Ultomiris 300 mg/3 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (1 adet), ULTOMIRIS ® RAVULIZUMAB 100MG/ML.